Published in final edited form as:

Clin Cancer Res. 2015 April 1; 21(7): 1549–1557. doi:10.1158/1078-0432.CCR-14-1186.

Nonviral Oncogenic Antigens and the Inflammatory Signals Driving Early Cancer Development as Targets for Cancer Immunoprevention

Nina J. Chu^{1,2}, Todd D. Armstrong¹, and Elizabeth M. Jaffee^{1,2}

¹Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland ²Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland

Abstract

Cancer immunoprevention is an emerging field that holds much promise. Within the last 20 years, prophylactic vaccines have been implemented on the population level for the immunoprevention of carcinomas induced by viruses, specifically hepatitis B virus (HBV) and human papillomavirus (HPV) infection. Armed with the success of prophylactic vaccines that prevent viral induced tumors, the field must overcome its next hurdle: to develop robust prophylactic vaccines that prevent the remaining >80% of human cancers not induced by viral infection. In this review, we discuss some of the most promising non-virus associated prophylactic vaccines that target endogenous neo-antigens including the earliest oncogene products, altered mucin 1 (MUC1) and α -enolase (ENO1), all of which produce new targets in the earliest stages of non-viral induced tumorigenesis. We also highlight a novel attenuated *Listeria monocytogenes*-based vaccine expressing mutant oncogene *Kras*^{G12D} (*LM-Kras*) effective in a pancreatic cancer model. A novel chimeric human/rat HER-2 plasmid vaccine (HuRT-DNA vaccine) effective in a breast cancer model is also discussed. In addition to prophylactic vaccine developments, this review highlights the potential use of classic drugs like aspirin and metformin as chemopreventive agents that can potentially be used as adjuvants to enhance the anti-cancer immunogenicity and efficacy of non-infectious prophylactic vaccines by modulating the inflammatory pathways within the early tumor microenvironment (TME) that propels tumorigenesis. Finally, timing of prophylactic vaccine administration is critical to its immunopreventive efficacy, providing a necessary role of current and emerging biomarkers for cancer screening and early cancer detection.

Corresponding Author: Elizabeth M. Jaffee, 4M07 Bunting Blaustein Cancer Research Building, 1650 Orleans Street, Baltimore, MD 21231. Phone: 410-955-2957; Fax: 410-614-8216; ejaffee@jhmi.edu.

Disclosure of Potential Conflicts of Interest: E.M. Jaffee has the potential to receive royalties, through her institution, for intellectual property related to *Listeria* mesothelin and GVAX vaccines that is owned by Johns Hopkins University and licensed to Aduro Biotech. No potential conflicts of interest were disclosed by the other authors.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Introduction

In the last two decades, significant progress has occurred in the field of cancer immunoprevention as evidenced by the success of prophylactic vaccines in preventing cancers caused by viral infection, so-called “infectious tumors” which account for 10-20% of all human tumors (1, 2). The most successful prophylactic vaccines targeting infectious tumors are effective against hepatitis B virus (HBV) and human papillomavirus (HPV) (1-3). The HBV specific prophylactic vaccine initially developed to prevent chronic acute hepatitis, had the unintentional favorable effect of dramatically reducing the incidence of post-hepatitis hepatocellular carcinoma (HCC) (1, 2). Conversely, the original intention for developing the prophylactic HPV vaccine was to prevent cervical cancer caused by persistent HPV infection. Hence, the HPV vaccine was the first “pure” implementation of human cancer immunoprevention (1). The recent population-based data indicating the efficacy of the HPV vaccine in Australia following the implementation of Australia's National HPV Vaccination Program in 2007 is very promising, and represents the first fully government-funded HPV vaccination program utilizing the prophylactic quadrivalent HPV vaccine Gardasil® (4-6). In 2011, the prevalence of vaccine-targeted HPV genotypes in women aged 18-24 was significantly lower in post-vaccinated women than in pre-vaccinated women (6.7% vs 28.7%) (4), while in 2014, the prevalence of HPV genotypes in post-vaccinated women further declined to 1.6% (5). Such significant reductions in HPV prevalence should be indicative of an eventual decrease in HPV-related cervical cancer incidence. Although the long-term cervical cancer preventing efficacy of the HPV vaccine has not yet been determined due to its recent worldwide administration, the results of clinical trials predict a near complete prevention of cancer occurrence (1). Since most human cancers are not induced by viral infection, and are therefore termed “non-infectious tumors”, the current goal of cancer immunoprevention is to translate the successes of prophylactic vaccine development from infectious tumor models to non-infectious tumors (2).

There are two reasons for the success of prophylactic vaccines that combat infectious tumors. First, they target known viral antigens involved in the tumorigenesis process (1). Second, they work when given to those at risk prior to exposure (1). Also critical is the fact that, in the case of HPV vaccine administration for the prevention of cervical cancer, the “at risk” group is essentially all young adults which removes the need for developing screening methods to identify a small “at risk” population who will benefit most from preventative vaccination (6). In contrast, there are a number of additional challenges that must be addressed to successfully develop prophylactic vaccines that target non-infectious tumors. The first is the need to identify the optimal tumor antigens that can serve as vaccine targets. Currently, most antigens that have been identified are not unique to the cancer, but are instead variations of or differentially expressed endogenous self-antigens (1, 2, 7, 8). Although these antigens may serve as targets for primary cancer prevention, they may also increase the risk of autoimmune responses to similar antigens expressed on normal tissue (1). Secondly, emerging data in animal models suggest that immune escape in the form of immune editing and immune tolerance mechanisms begin early in cancer development, at the time of the first genetic alteration that initiates the cascade of genetic and inflammatory

changes that eventually lead to cancer development (9-11). Thus, it is likely that any vaccine that targets a non-infectious tumor promoting antigen will likely need to be given with other agents that modulate the early inflammatory tumor microenvironment (TME) and precancerous mechanisms of immune evasion (9). This challenge raises the need for biomarkers that can identify populations at risk for a given cancer type and who will benefit most from early immune based interventions. However, with careful selection of oncogenic antigen targets that are specific “driver” gene products that arise early in a particular cancer's development, adjuvant regulation of the inflammatory TME, and robust diagnostic and prognostic screening for the early detection of cancer, there is great potential for the successful development of prophylactic vaccines that prevent non-virally induced tumorigenesis.

Antigen targets for prophylactic vaccine development

The first step toward the design of effective vaccines for cancer prevention is the selection of the antigen target. An optimal antigen target should be an early alteration in a normal gene that is likely an initiator (driver) or facilitator of tumor development to ensure that the immune response is directed toward a “causative” signal without which the developing tumor cannot survive. Vaccination of such a target is likely to produce an immunopreventive response that is both efficacious and the least toxic, mounting a focused and concerted immune response to early neoplasms (1, 8). The difficulty lies in predicting the earliest antigenic profile of developing tumors and discovering such antigens that are dysregulated in the earliest stages of tumorigenesis, along with their differential expression amongst other cell types. However, the rapidly progressing field of cancer genetics is uncovering the earliest cancer driver genes and their expressed neo-antigens associated with the development of different cancers. The various methods utilized to discover potential cancer driver genes and their expressed antigenic targets are discussed in detail elsewhere (12-14). Currently, there are sets of known driver gene antigens for some cancers that are classified according to their tumor/normal tissue exclusivity and cellular localization (Table 1). Tumor specific antigens (TSA) are antigens that are exclusively expressed on tumor cells and not on any other cells (8). TSAs are often mutated proteins, such as Kras^{G12D} and p53 (3). Tumor associated antigens (TAA) are endogenous antigens present on both tumor and normal cells but are dysregulated in their expression or cellular localization. The HER-2/*neu* receptor is one example of a TAA (3, 8). As progress in cancer immunotherapy and immunoprevention have greatly accelerated in the last two decades, a novel class of antigens, oncoantigens, has been defined in the context of vaccine therapy. Oncoantigens are antigens that must support tumor growth and are specifically expressed extracellularly or on the cell surface (1, 15). Oncoantigens are thought to be the most suitable targets for immunopreventive vaccines due to their requisite roles in driving tumorigenesis and their accessible location to elicit immune responses (15).

Cancer-testis (CT) antigens are a class of promising TAAs that are currently being investigated for their potential to be candidate novel targets used for therapeutic and prophylactic vaccine development (16). CT antigens are predominantly expressed in the testis but are also found in the ovary and trophoblast, having cellular functions in transcriptional regulation, recombination, apoptosis, adherence, and cell mobility (16).

These antigens are over-expressed in a variety of different tumors, while minimally expressed in normal tissues. Hence, this emerging class of antigens represents attractive targets that can be used for cancer vaccine development (16). Two CT antigens, MAGE-A3 and NY-ESO-1, have already been classified by the National Cancer Institute as being amongst the top 10 antigens in the Project for the Prioritization of Cancer Antigens and are currently being tested in clinical trials for their immunotherapeutic efficacy in combination with adjuvants (16, 17). Much work needs to be done to determine which CT antigens are specifically oncoantigens. For many CT antigens, their fundamental roles in driving tumorigenesis along with their cellular localization have yet to be determined. These antigen characteristics will influence the type and strength of immunological responses produced against them when used as immune targets (16).

Vaccines: Emerging and Currently Under Development

Several promising non-infectious prophylactic vaccines are under development and are targeting TSAs, TAAs, and oncoantigens. Specific targets include: Kras^{G12D}, HER-2/*neu*, MUC1, and ENO1. In addition to the type of antigen, there are a number of antigen-delivery approaches being tested that take advantage of the immune system's best mechanisms for activating potent adaptive and innate immune responses. It is not yet clear which of these delivery systems offers the best immunity and safety profiles. Different delivery systems have been extensively discussed in other reviews (18-20). We will highlight only a few that target the categories of antigens that hold promise for primary prevention with emphasis on studies conducted in subjects at risk for a particular cancer.

Listeria monocytogenes vector engineered to target mutated Kras (Kras^{G12D}, LM-Kras)

Keenan and colleagues developed a vaccine composed of recombinant attenuated intracellular bacterium *Listeria monocytogenes* (LM) engineered to express the most common mutation found in the oncogene Kras, Kras^{G12D}, to test as prevention in a preclinical model of pancreatic ductal adenocarcinoma (PDA). The mutant Kras^{G12D} was chosen as the antigenic target because it is the earliest and most prevalent mutant oncogene in PDA development (21). The *Kras*^{G12D/+}; *Trp53*^{R172H/+}; *Pdx-1-Cre* (KPC) mice are genetically programmed to spontaneously develop tissue specific PDA following the earliest mutation which is Kras^{G12D}, and exhibit a natural stepwise progression from pre-malignant pancreatic intraepithelial neoplasias (PanINs) to invasive PDA (21). LM was utilized as a vehicle to express the driver Kras^{G12D} gene due to its ability to induce robust CD4⁺ and CD8⁺ T-cell immunity via its selective infection of antigen presenting cells (APC) over non-phagocytic cells, thereby maintaining immunogenicity while significantly decreasing toxicity (21-23). The LM-Kras vaccine was administered either alone or with regulatory T cell (Treg) depletion since Tregs were shown to be an early inhibitor of immune infiltration into PanINs in this model of PDA development (11). Mice received treatment either at the time of the earliest genetic change (PanIN 1) or at the time of late stage PanIN development. Mice that received LM-Kras in combination with Treg depletion at the earliest time point had significantly prolonged survival accompanied by decelerated PanIN progression compared to KPC mice that were either unvaccinated, given LM-Kras alone, or given

combination treatment at the time of later stage PanIN development (21). These results demonstrate that after the first genetic alteration occurs in neoplastic cells, prophylactic immune based vaccination requires combination therapy to alter the already inflammation prone early TME. This study also highlights the importance of identifying the optimal time for administering a prophylactic vaccine, which will require biomarkers to identify the population at risk for early pre-malignant changes. A drawback to this model is that the Kras^{G12D} mutation is present from birth. Further research using inducible Kras^{G12D} gene products will allow for a more realistic test of a preventative Kras-specific vaccine (24).

Chimeric human/rat HER-2 plasmid

Despite the widespread clinical use of HER-2 targeted small molecule inhibitors and monoclonal antibodies, trastuzumab and pertuzumab, there remains a lack of HER-2/neu prophylactic and therapeutic vaccines implemented in the clinic (25, 26). In a study conducted by Giovanni et al., FVB-huHER2 transgenic mice were vaccinated with tumor cells expressing human HER-2 with recombinant IL-12 adjuvant (HER-2 cell vaccine) or chimeric human/rat HER-2 DNA plasmid (HuRT-DNA vaccine) (25). The FVB-huHER2 mice over-express the human HER-2 gene and spontaneously develop mammary tumors within the first 6 months of life, making FVB-huHER2 mice a suitable model to study immunoprevention of tumorigenesis through huHER-2 targeting prophylactic vaccines (25). Mice vaccinated with the HuRT-DNA vaccine had the longest mean tumor-free survival, compared to mice vaccinated with either HER-2 cell vaccine or mock vaccination (25). The HuRT-DNA vaccinated mice also had a significant reduction of mammary tumors per mouse and produced a high level of anti-huHER-2 antibodies compared to HER-2 cell vaccinated mice (25). The serum isolated from HuRT-DNA vaccinated mice was able to inhibit the growth of huHER-2 positive tumors in immunodeficient xenograft-carrying mice (25). The results of this study show that chimeric human/rat HER-2 plasmid vaccine is a promising immunopreventative treatment for its ability to break immunological tolerance to huHER-2 in a huHER-2 tolerant host (25, 26). The chimeric human/rat HER-2 plasmid vaccine can also generate robust memory via production of high levels of specific anti-huHER-2 antibodies, which is an important component of any preventive vaccine (25).

MUC1

MUC1 is a mucin-like, glycosylated TAA that is overexpressed in several epithelial carcinomas including breast, colon, lung, prostate, and ovarian carcinomas (3, 27, 28). The posttranslational modifications of MUC1 define its tumorigenicity (3, 27). For example, in normal colon epithelial cells, MUC1 is hyperglycosylated, whereas in neoplastic cells lacking luminal polarity, MUC1 is hypoglycosylated (3, 27). A human-based clinical study demonstrated that in patients without colon cancer, but with a history of advanced colorectal adenoma, administration of a prophylactic vaccine synthesized with 100mer MUC1 peptide in combination with poly-L-lysine and carboxymethylcellulose (Poly-ICLC) adjuvant, a toll like receptor (TLR) 3 agonist, produced a strong adaptive and memory immune response evidenced by high levels of anti-MUC1 IgG antibody production (27). Additionally, efficacy of the MUC1 peptide vaccine did not elicit significant adverse effects, such as autoimmune disease post-vaccination (27). Patients who failed to respond to the vaccine, evidenced by no

increase in production of anti-MUC1 IgG antibody, also had high levels of circulating myeloid derived suppressor cells (MDSCs) before vaccination (27). High levels of this immunosuppressive cell population dampen anti-tumor adaptive immunity (29), thereby decreasing the immunogenicity of the MUC1 peptide vaccine (27). Thus, this study provides evidence in patients that in order to realize the success of vaccines for primary prevention, it will necessitate the addition of adjuvants/immune modulators that decrease immunosuppression (29). The results of this study demonstrate the ability of the MUC1 peptide vaccine in combination with the Poly-ICLC adjuvant to strongly activate the adaptive immune response without significant adverse effects, while generating immune memory to the oncogenic antigen. These mechanisms may underlie the prophylactic potential of MUC1 peptide vaccines in reducing recurrence of premalignant lesions leading to the eventual prevention of colorectal cancer, which must be shown by prolonged monitoring of cancer occurrence in vaccinated patients. This study further highlights the need to consider ways to alter suppressive immune cell populations like MDSCs simultaneously at the time of preventive vaccination when the host has already been exposed to the initiating genetic alteration.

ENO1

ENO1, or α -enolase, is a TAA that has dual roles depending on its cellular location of expression. ENO1 functions as a glycolytic enzyme in the cytoplasm, while on the membrane, it functions as a plasminogen receptor affecting cell migration and metastasis (30-32). Overexpression of ENO1 is observed in a variety of cancers, including brain, breast, colon, gastric, head and neck, kidney, liver, lung, ovary, pancreas, prostate, and skin amongst others (31). Like MUC1, ENO1 is also subject to posttranslational modifications which, depending on type, determines its overexpression in specific cancer types (31). To assess the potential of utilizing ENO1 as a TAA for prophylactic vaccine development, KPC mice were vaccinated with ENO1 plasmid at 4 weeks of age, when early PanINs are prevalent (30). ENO1 plasmid vaccine was able to significantly increase mean survival times by delaying onset of PDA (30). Vaccine immunogenicity was confirmed by high serum levels of anti-ENO1 IgG antibody, which induced complement-mediated cytotoxicity of antibody-bound cancer cells (30). Despite the low expression of endogenous ENO1 on normal cells, the humoral and cellular ENO1-specific CD8⁺ cytotoxic T lymphocytes (CTLs) produced by the ENO1 plasmid vaccine spared normal cells and lysed only cancer cells overexpressing ENO1 (30, 32). The specific cytotoxicity achieved by this vaccine avoided the autoimmunity that is normally associated with TAA targeting vaccines. Additionally, the ENO1 plasmid vaccine reduced the expansion of MDSCs and Tregs, while promoting T-helper 1 (Th1) and 17 (Th17) responses (30). This study exhibits the dual potential of ENO1 plasmid vaccines to concurrently prevent onset of PDA and down-modulate immunosuppressive, pro-tumorigenic cell populations.

Early Genetic Changes Lead to Early Inflammation

Early tumorigenesis is the result of the initiation of early genetic alterations, namely activation of oncogenes and/or silencing of tumor suppressors that not only initiate carcinogenesis in the tumor cells themselves, but also induce a cascade of inflammatory

events that create an early TME that supports and propagates tumor development (9, 10). This TME is created by inflammatory signals that recruit suppressive immune cell populations and non-neoplastic stromal cells that enhance tumor growth, while dampening immune activation, even in the earliest pre-malignant stages (9, 10). Studies have shown that the early activation of oncogenic drivers such as mutant Kras in neoplastic cells is sufficient to initiate the formation of the early TME in response to inflammatory signaling, and that *in vivo* silencing of mutant Kras in early pre-malignant lesions completely and rapidly reverses the transformed ductal epithelium and desmoplastic stroma in transgenic mouse models of PDA and lung adenocarcinoma (24). PDA is a cancer model that is characterized by extensive fibroinflammatory stroma that mediates its resistance to chemotherapies (24, 33). Kras^{G12D} is the earliest and most persistent oncogenic mutation throughout PDA progression, present in at least 92% of early stage PanINs and remains expressed in late stage PanINs (34). Early mutant Kras-driven neoplastic cells secrete cytokines, interleukin (IL)-8, IL-6, and granulocyte macrophage colony stimulating factor (GM-CSF), which recruits Tregs and MDSCs to the TME (10, 24, 35, 36). These immunosuppressive cell populations maintain and propagate tumorigenesis by promoting immune tolerance and escape, while preventing the infiltration of activated CD4⁺ and CD8⁺ T-cells to the early TME (11). Despite the presence of activated T-cells in the periphery induced by treatment, the non-permissive TME created by these immunosuppressive cell populations prevents the infiltration of activated T-cells into the TME to perform antigen-specific killing of tumor cells (9). Therefore, in order for non-infectious prophylactic vaccines to achieve maximal immunogenicity and anti-cancer efficacy, the early targeting of activated oncogenic drivers needs to be coupled with the modulation of the early inflammatory immunosuppressive TME that may otherwise hinder effective treatment.

Agents for Chemoprevention that Alter Early Inflammation in Premalignancies

The immune modulating antibodies that alter signals like cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death-1 (PD-1) receptor in the TME are successful treatment approaches for patients with existing cancer resistant to other therapeutic modalities (37). These agents act on previously induced T cells (37). Although they are providing durable treatment effects in patients with metastatic cancers, their utility as agents for primary prevention is currently limited by their serious autoimmune toxicity profiles (38). In addition, it is not clear that signals like CTLA-4 and PD-1 are the most important signals for modulation in the early developing TME. Therefore, agents that have lower risk for severe toxicities and that alter the earliest inflammatory changes will be the most successful for evaluation in healthy patients at risk for cancers.

Some chemopreventive agents have exhibited immunopreventive potential in cancer models and may be used as adjuvants to create an anti-inflammatory, permissive TME for increased prophylactic vaccine efficacy. Two agents, in particular, aspirin and metformin, that are widely used for the treatment of non-cancer related inflammatory diseases, may prevent tumorigenesis via anti-inflammatory mechanisms when given chronically.

Aspirin

Aspirin belongs to the class of non-steroidal anti-inflammatory drugs (NSAIDs) that irreversibly inactivates cyclooxygenase (COX) 1 and 2 to prevent the synthesis of prostanoids, including prostaglandins, prostacyclin, and thromboxane A (29, 39, 40). Aspirin's inhibition of these metabolites produces its analgesic, antipyretic, anti-inflammatory, and cardiovascular effects (39, 40). Several clinical studies have shown that a safe daily low-dose of aspirin, taken for the prevention of cardiovascular disease, also decreases the incidence and recurrence of colorectal cancer (39, 40). Additionally, meta-analysis of cardiovascular trials revealed that a daily low-dose of aspirin may reduce cancer incidence and cancer mortality from all cancers combined (39, 40). Aspirin's chemopreventive effects result from its modulation of inflammatory signaling pathways that regulate the TME. Aspirin suppresses the pro-inflammatory NF κ B and STAT3 pathways involved in cancer initiation (41, 42), while preventing PGE₂-mediated differentiation of immature human monocytes into immunosuppressive MDSCs (29).

Metformin

Metformin, a widely used treatment for type II diabetes mellitus, prevents tumorigenesis via two primary mechanisms: alteration of tumor metabolism by inhibiting mechanistic target of rapamycin (mTOR) through AMP-activated protein kinase (AMPK) modulation; and inhibition of pro-inflammatory cancer-promoting NF κ B and STAT3 pathways (42-44). The NF κ B/STAT3 signaling pathway plays a critical role in inflammation-mediated carcinogenesis. Several studies have demonstrated that the NF κ B/STAT3 pathway is activated by oncogenic driver genes, such as *Kras*, and secretion of specific cytokines, IL-6 and IL-11, by early lesions and tumor infiltrating immune cells in an autocrine and paracrine fashion (42). Hence, it is through inhibition of neoplastic cell metabolism and early inflammation within the TME that allows Metformin to reduce the prevalence of a variety of cancers, including PDA, hepatocellular carcinoma (HCC), melanoma, and triple-negative breast cancer (TNBC) (42, 43, 45-47). These studies support metformin's potential as an adjuvant chemopreventive drug to enhance the efficacy of non-infectious tumor targeting vaccines.

Timing of Immunopreventive Vaccine Administration Requires Cancer Screening

Synthesizing a potent prophylactic vaccine that selectively elicits an immune response to target oncoantigens to eliminate potential neoplastic cells, while utilizing adjuvants in combination to modulate the inflammatory composition of the TME, is vital to the success of cancer immunoprevention. Tantamount to vaccine development is precise timing of vaccine administration. Studies have shown that early administration of prophylactic vaccines, before exposure to the causative agent (ie virus), can effectively prevent cancer occurrence (1,2). More recently, vaccination of KPC mice that have an existing *Kras* mutation that initiates tumor development with an LM-*Kras* vaccine, slows progression to PDA if early inflammatory changes are also halted (21). This finding provides an explanation for why infectious vaccines that work well for preventing cancers prior to

exposure to the virus do not as single agents prevent even early cancerous changes from progressing to cervical cancer and HPV⁺ oropharynx carcinoma (OPC) (20). Early vaccine administration aids in shifting immune control towards prolonged equilibrium or full elimination, reducing immune evasion and tumor escape (1, 7). Timing of administration is critical to achieve optimal prophylactic vaccine efficacy, hence identification of specific diagnostic and prognostic biomarkers for cancer screening is of significant importance to the success of cancer immunoprevention. These biomarkers will need to identify the early inflammatory changes and the regulators of the early genetic, epigenetic, and inflammatory changes that facilitate cancer development. Certain at-risk populations that are characterized by family history of cancer incidence as well as personal history of pre-malignant lesions are of particular interest as candidates for early prevention by vaccines.

In addition to oncogenic genetic drivers that initiate carcinogenesis via an inflammatory TME, epigenetic modifications of DNA and the associated proteins are mechanisms of immune evasion that can not only be utilized as biomarkers for cancer screening, but also be targeted for adjuvant therapies that enhance the efficacy of prophylactic vaccines by regulating the polarity of inflammatory cells within the TME (48-50). Recent studies have elucidated the role of histone deacetylases (HDACs) in defining the phenotype of cancer-associated MDSCs and regulating the expression of OX40L by malignant cells, IL-10 by Tregs, and antigen presentation by tumor cells (48, 50-54). Thus, modulation of the early immunosuppressive TME by epigenetic agents can increase the immunogenicity of tumor cells and augment the antitumor properties of immune cells. Furthermore, additional efforts are required to further elucidate the role of these epigenetic changes as biomarkers for identifying “at risk” populations.

Emerging Epigenetic Markers for Potential Screening of Early Cancers

microRNAs

Recently studies have identified epigenetic signatures, specifically microRNA (miRNA) profiles and methylation patterns of a variety of cancers that have the potential to be used for novel non-invasive methods of cancer screening. miRNAs are short endogenous non-coding RNAs that are approximately 20 nucleotides in length that negatively regulate protein expression by inhibiting translation and/or by targeting mRNAs for degradation (55). Alterations in miRNA expression are important for cancer development and cancer-specific miRNA profiles have been uncovered that propagate and are associated with certain cancer types (56). The non-invasive isolation of circulating miRNAs from a simple blood draw along with its stability in harsh conditions (freeze-thawing, RNase digestion, wide pH range) confers feasibility to utilizing circulating miRNAs for cancer screening in the clinic (57, 58).

DNA Methylation

DNA methylation patterns are also promising diagnostic and prognostic biomarkers for cancer screening. DNA methylation is an epigenetic modification in which methylation occurs at cytosine residues of cytosine-phosphate-guanine dinucleotides (CpG islands), transcriptionally silencing genes (59-61). Hypermethylation of tumor suppressor genes and hypomethylation of oncogenes are mechanisms of tumorigenesis, and specific DNA

methylation patterns are characteristic of varying cancers (60, 61). DNA methylation signatures can be found in any biological tissue sample or bodily fluid, which facilitates screening (59). DNA methylation is one of the most robust epigenetic marks and, like circulating miRNAs, is resistant to harsh conditions, withstanding most storage conditions (59). Therefore, DNA methylation's wide biological prevalence and stability, make it also a potential biomarker for clinical cancer screening.

Challenges

Despite the advances made in prophylactic vaccine development, elucidation of inflammatory dynamics within the developing TME, chemoprevention, and biomarker discovery, there remain challenges that need to be overcome in order to advance the cancer immunoprevention field. A significant challenge that necessitates further investigation is precisely when or how early along the developmental timeline should prophylactic vaccines for non-viral cancers be administered in order to achieve optimal immunoprevention. The ideal time point together with the composition of the procarcinogenic inflammatory response at that time point for the administration of non-viral tumor targeting prophylactic vaccines needs to be established. A proposed time line for prophylactic vaccine administration within the context of a genetic and inflammatory cancer progression model is depicted in Fig. 1.

For non-infectious cancers, a major risk associated with using TAAs as targets for prophylactic vaccines in combination with adjuvants is autoimmune toxicity (1). Since TAAs are expressed on both normal cells and neoplastic cells, a robust vaccine-elicited immune response targeting self-antigens may induce autoimmunity (1, 8). Adjuvants such as cytokine therapy, immune checkpoint blockade, and chemotherapeutic agents enhance the immunopreventive efficacy of prophylactic vaccines by inhibiting immunosuppressive cell populations, creating a more permissive TME, and increasing immunosurveillance to reduce tumor evasion (3, 9, 21, 29). Particular advances have been made in the field of developing immune checkpoint inhibitors, such as antibodies against CTLA-4 and the receptor/ligand axis, PD-1/PD-L1, to reduce the inhibition that these receptor/ligand pairs exert on T cell activation (37). Although immune checkpoint blockade has proven to be successful as a therapy, both alone and in combination, in various advanced cancers, particularly in melanoma, specific “immune-related adverse events” (irAEs) are induced that mainly include high grade gastrointestinal, hepatic, and endocrine toxicities as a result of breaking immunological tolerance upon administration of such antibodies.⁵¹ These high grade irAEs will particularly be a problem if immune checkpoint inhibitors are given long-term in a preventative setting in combination with non-infectious prophylactic vaccines. The heightened immune activation triggered by such adjuvants to enhance vaccine immunogenicity may further contribute to autoimmunity (3, 29, 38). In addition to autoimmunity, toxicity is an issue with prolonged use of other antigen non-specific adjuvants, specifically cytokine therapy (1, 20). Cytokine toxicity, like immune checkpoint blockade toxicities, is a challenge particularly for cancer immunoprevention because prophylactic treatment may necessitate chronic lifelong dosing (1, 20). Prophylactic vaccine efficacy can also be compromised by hypermutation of TSAs, low frequency of oncoantigen over-expression, and heterogeneous intra-tumoral oncoantigen expression (2).

A challenge in the area of circulating miRNA and DNA methylation biomarker discovery for early cancer screening is identifying signatures that will not only identify the presence of pre-cancer, but also be indicative of stage and/or progress of the pre-cancer, along with its tissue-specificity. This level of detail and specificity has yet to be achieved. Epigenetic profiles need to be established in a cancer developmental context to aid in ascertaining the ideal time for vaccine administration in transgenic mice and human models. Additionally, consistency needs to be established for circulating miRNA sample processing and quantification. Currently, there are inconsistencies with miRNA isolation from serum or plasma (56, 62). There is also debate as to what is the most suitable standard or endogenous control for qRT-PCR, which would affect accurate quantification (56, 62). Developing reference procedures to standardize processing and analysis will be necessary in order for accurate comparisons between independent laboratories.

Conclusions

The field of cancer immunoprevention has made great advances in developing successful prophylactic vaccines that elicit immune responses to prevent infectious tumors. The worldwide population level administration of HBV vaccines have significantly reduced the occurrence of HCC, and clinical trials predict the near 100% prevention of cervical carcinogenesis in patients vaccinated with HPV vaccines. The success of prophylactic vaccines in preventing the occurrence of infectious tumors lies in the vaccine's ability to induce specific immune recognition and attack of viral antigens. However, a current challenge facing the field of immunoprevention is developing effective, safe, and immunogenic prophylactic vaccines that target endogenous oncoantigens overexpressed by non-infectious tumors, which account for the majority of human cancers. The efficacy of infectious vaccines is also determined by the inflammatory composition of the early TME initiated and propagated by early oncogenic driver genes. Hence, aspirin and metformin may be promising chemopreventive adjuvants that aid prophylactic vaccine efficacy by down-regulating early local inflammatory pathways while exhibiting a safer toxicity profile when compared with immune modulating agents that are approved for cancer treatment. Potential exists to combine these chemopreventive anti-inflammatory agents with antigen-targeted vaccines as a means to delay or prevent the onset of tumorigenesis.

The early administration of prophylactic vaccines, before the onset of tumorigenesis, has proven to significantly affect the degree of anti-cancer protection. Therefore, cancer screening methods for detection of the earliest pre-malignant changes are needed to fully implement immune based interventions for primary cancer prevention. Epigenetic signatures, particularly circulating miRNA subsets and DNA methylation status of gene promoters, are emerging as powerful diagnostic indicators of early cancers. Further studies are needed to determine when to vaccinate along the cancer developmental timeline for prophylactic vaccines to cause maximal immunoprevention. This knowledge, aided by more predictive screening methods, and an improved understanding of the procarcinogenic inflammatory changes that help shape the developing TME, will propel the field of immunoprevention into the mainstream.

Acknowledgments

Grant Support: E.M. Jaffee was supported by the NCI of the NIH under award numbers R01CA184926 and P50CA062924; the Skip Viragh Center for Pancreas Cancer, Clinical Research, and Patient Care; and a Stand Up To Cancer–Lustgarten Foundation Pancreatic Cancer Convergence Dream Team Translational Research Grant (SU2C-AACR-DT1414). Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research.

References

1. Lollini PL, Nicoletti G, Landuzzi L, Cavallo F, Forni G, Giovanni C, et al. Vaccines and other immunological approaches for cancer immunoprevention. *Curr Drug Targets*. 2011; 12:1957–73. [PubMed: 21158706]
2. Tuohy VK, Jaini R. Prophylactic cancer vaccination by targeting functional non-self. *Ann Med*. 2012; 43:356–65. [PubMed: 21651440]
3. Weiner LM, Surana R, Murray J. Vaccine prevention of cancer: can endogenous antigens be targeted? *Cancer Prev Res*. 2010; 3:410–5.
4. Tabrizi SN, Brotherton JML, Kaldor JM, Skinner SR, Cummins E, Liu B, et al. Fall in human papillomavirus prevalence following a national vaccination program. *J Infect Dis*. 2012; 206:1645–51. [PubMed: 23087430]
5. Osborne SL, Tabrizi SN, Brotherton JML, Cornall AM, Wark JD, Wrede CD, et al. Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program. *Vaccine*. 2015; 33:201–8. [PubMed: 25444787]
6. Garland SM, Skinner SR, Brotherton JML. Adolescent and young adult HPV vaccination in Australia: achievements and challenges. *Prev Med*. 2011; 53:S29–35. [PubMed: 21962468]
7. Finn OJ. Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic. *Cancer Immunol Res*. 2014; 2:708–13. [PubMed: 25092812]
8. Farkas AM, Finn OJ. Vaccines based on abnormal self-antigens as tumor-associated antigens: immune regulation. *Semin Immunol*. 2010; 22:125–31. [PubMed: 20403708]
9. Keenan BP, Jaffee EM, Armstrong TD. Tumor immunology: multidisciplinary science driving basic and clinical advances. *Cancer Immunol Res*. 2013; 1:16–23. [PubMed: 24409447]
10. Keenan B, Jaffee EM. Immunotherapy in preneoplastic disease: targeting early procarcinogenic inflammatory changes that lead to immune suppression and tumor tolerance. *Ann N Y Acad Sci*. 2013; 1284:12–6. [PubMed: 23651188]
11. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. *Cancer Res*. 2007; 67:9518–27. [PubMed: 17909062]
12. Siewert K, Malotka J, Kawakami N, Wekerle H, Hohlfeld R, Dornmair K. Unbiased identification of target antigens of CD8+ T cells with combinatorial libraries coding for short peptides. *Nat Med*. 2012; 18:824–8. [PubMed: 22484809]
13. Castle JC, Kreiter S, Diekmann J, Lower M, Roemer N, Graaf J, et al. Exploiting the mutanome for tumor vaccination. *Cancer Res*. 2012; 72:1081–91. [PubMed: 22237626]
14. Hacohen N, Fritsch EF, Carter TA, Lander ES, Wu CJ. Getting personal with neoantigen-based therapeutic cancer vaccines. *Cancer Immunol Res*. 2013; 1:11–5. [PubMed: 24777245]
15. Lollini PL, Nicoletti G, Landuzzi L, De Giovanni C, Nanni P. Immunoprevention and immunotherapy of mammary carcinoma. *Breast J*. 2010; 16:S39–41. [PubMed: 21050308]
16. Ghafouri-Fard S, Shamsi R, Seifi-Alan M, Javaheri M, Tabarestani S. Cancer-testis genes as candidates for immunotherapy in breast cancer. *Immunotherapy*. 2014; 6:165–79. [PubMed: 24491090]
17. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. *Clin Cancer Res*. 2009; 15:5323–37. [PubMed: 19723653]

18. Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, et al. Therapeutic vaccines for cancer: an overview of clinical trials. *Nat Rev Clin Oncol*. 2014; 11:509–24. [PubMed: 25001465]
19. Patel SP, Osada T, Lyerly HK, Morse MA. Designing effective vaccines for colorectal cancer. *Immunotherapy*. 2014; 6:913–26. [PubMed: 25313570]
20. Gildener-Leapman N, Lee J, Ferris RL. Tailored immunotherapy for HPV positive head and neck squamous cell cancer. *Oral Oncol*. 2014; 50:780–4. [PubMed: 24126224]
21. Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, et al. A *Listeria* vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. *Gastroenterology*. 2014; 146:1784–94. [PubMed: 24607504]
22. Singh R, Paterson Y. *Listeria monocytogenes* as a vector for tumor-associated antigens for cancer immunotherapy. *Expert Rev Vaccines*. 2006; 5:541–52. [PubMed: 16989634]
23. Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, et al. *Listeria*-based cancer vaccines that segregate immunogenicity from toxicity. *Proc Natl Acad Sci U S A*. 2004; 101:13832–7. [PubMed: 15365184]
24. Collins MA, Bednar F, Zhang Y, Brisset JC, Galban S, Galban CJ, et al. Oncogenic *Kras* is required for both the initiation and maintenance of pancreatic cancer in mice. *J Clin Invest*. 2012; 122:639–53. [PubMed: 22232209]
25. De Giovanni C, Nicoletti G, Quaglino E, Landuzzi L, Palladini A, Lucia Ianzano M, et al. Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2. *Breast Cancer Res*. 2014; 16:R10. [PubMed: 24451168]
26. Occhipinti S, Sponton L, Rolla S, Caorsi C, Novarino A, Donadio M, et al. Chimeric rat/human HER2 efficiently circumvents HER2 tolerance in cancer patients. *Clin Cancer Res*. 2014; 20:2910–21. [PubMed: 24668647]
27. Kimura T, McKolanis JR, Dzubinski LA, Islam K, Potter DM, Salazar AM, et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study. *Cancer Prev Res*. 2014; 6:18–26.
28. Kovjazin R, Horn G, Smorodinsky NI, Shapira MY, Carmon L. Cell surface-associated anti-MUC1-derived signal peptide antibodies: implications for cancer diagnostics and therapy. *PLoS One*. 2014; 9:e85400. [PubMed: 24416403]
29. Marzbani E, Inatsuka C, Lu H, Disis ML. The invisible arm of immunity in common cancer chemoprevention agents. *Curr Drug Targets*. 2014; 6:764–73.
30. Cappello P, Rolla S, Chiarle R, Principe M, Cavallo F, Perconti G, et al. Vaccination with ENO1 DNA prolongs survival of genetically engineered mice with pancreatic cancer. *Gastroenterology*. 2013; 144:1098–106. [PubMed: 23333712]
31. Capello M, Ferri-Borgogno S, Cappello P, Novelli F. α -Enolase: a promising therapeutic and diagnostic tumor target. *FEBS J*. 2011; 278:1064–74. [PubMed: 21261815]
32. Cappello P, Tomaino B, Chiarle R, Ceruti P, Novarino A, Castagnoli C, et al. An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen. *Int J Cancer*. 2009; 125:639–48. [PubMed: 19425054]
33. Pasca Di Magliano M, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. *Gastroenterology*. 2013; 144:1220–9. [PubMed: 23622131]
34. Kanda M, Matthaei H, Wu J, Hong SM, Yu J, Borges M, et al. Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. *Gastroenterology*. 2012; 142:730–3. [PubMed: 22226782]
35. Holmer R, Goumas FA, Waetzig GH, Rose-John S, Kalthoff H. Interleukin-6: a villain in the drama of pancreatic cancer development and progression. *Hepatobiliary Pancreat Dis Int*. 2014; 13:371–80. [PubMed: 25100121]
36. Zheng L, Xue J, Jaffee EM, Habtezion A. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. *Gastroenterology*. 2013; 144:1230–40. [PubMed: 23622132]

37. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. *Clin Cancer Res.* 2013; 19:5300–9. [PubMed: 24089443]
38. Gelao L, Criscitiello C, Esposito A, Goldhirsch A, Curigliano G. Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an “innocent bystander”. *Toxins.* 2014; 6:914–33. [PubMed: 24594636]
39. Sostres C, Gargallo CJ, Lanas A. Aspirin, cyclooxygenase inhibition and colorectal cancer. *World J Gastrointest Pharmacol Ther.* 2014; 5:40–9. [PubMed: 24605250]
40. Thun MJ, Jacobs EJ, Patrono C. The role of aspirin in cancer prevention. *Nat Rev Clin Oncol.* 2012; 9:259–67. [PubMed: 22473097]
41. Hoesel B, Schmid JA. The complexity of NF- κ B signaling in inflammation and cancer. *Mol Cancer.* 2013; 12:86. [PubMed: 23915189]
42. Yue W, Yang CS, DiPaola RS, Tan XL. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. *Cancer Prev Res.* 2014; 7:388–97.
43. Mohammed A, Janakiram NB, Brewer M, Ritchie RL, Marya A, Lightfoot S, et al. Antidiabetic drug metformin prevents progression of pancreatic cancer by targeting in part cancer stem cells and mTOR signaling. *Transl Oncol.* 2013; 6:649–59. [PubMed: 24466367]
44. Pulito C, Sanli T, Rana P, Muti P, Blandino G, Strano S. Metformin: on ongoing journey across diabetes, cancer therapy and prevention. *Metabolites.* 2013; 3:1051–75. [PubMed: 24958265]
45. Hsieh SC, Tsai JP, Yang SF, Tang MJ, Hsieh YH. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF- κ B-dependent pathway that reduces uPA and MMP-9 expression. *Amino Acids.* 2014; 46:2809–22. [PubMed: 25245054]
46. Litzenburger BC, Brown PH. Advances in preventive therapy for estrogen-receptor-negative breast cancer. *Curr Breast Cancer Rep.* 2014; 6:96–109. [PubMed: 24829621]
47. Reddi A, Powers MA, Dellavalle RP. Therapeutic potential of the anti-diabetic agent metformin in targeting the skin cancer stem cell diaspora. *Exp Dermatol.* 2014; 23:345–6. [PubMed: 24521225]
48. Kosoff D, Krueger T, Lang JM. Targeting epigenetic mechanisms for clinical translation: enhancing the efficacy of tumor immunotherapies. *Immunotherapy.* 2013; 5:1243–54. [PubMed: 24188678]
49. Lou E, Subramanian S, Steer CJ. Pancreatic cancer modulation of KRAS, microRNAs, and intercellular communication in the setting of tumor heterogeneity. *Pancreas.* 2013; 42:1218–26. [PubMed: 24152947]
50. Youn JI, Kumar V, Collazo M, Nefedova Y, Condamine T, Cheng P, et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. *Nat Immunol.* 2013; 14:211–20. [PubMed: 23354483]
51. Khan ANH, Tomasi TB. Histone deacetylase regulation of immune gene expression in tumor cells. *Immunol Res.* 2008; 40:164–78. [PubMed: 18213528]
52. Villagra A, Cheng F, Wang HW, Suarez I, Glogzak M, Maurin M, et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. *Nat Immunol.* 2009; 10:92–100. [PubMed: 19011628]
53. Wang H, Cheng F, Woan K, Sahakian E, Merino O, Rock-Klotz J, et al. Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10. *J Immunol.* 2011; 186:3986–96. [PubMed: 21368229]
54. Buglio D, Khaskhely NM, Voo KS, Martinez-Valdez H, Liu YJ, Younes A. HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. *Blood.* 2011; 117:2910–7. [PubMed: 21239696]
55. Yu J, Li A, Hong SM, Hruban RH, Goggins M. MicroRNA alterations of pancreatic intraepithelial neoplasias. *Clin Cancer Res.* 2012; 18:981–92. [PubMed: 22114139]
56. Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. *Adv Drug Deliv Rev.* 2015; 81C:75–93. [PubMed: 25220354]

57. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. *Cell Res.* 2008; 18:997–1006. [PubMed: 18766170]
58. Sita-Lumsden A, Dart DA, Waxman J, Bevan CL. Circulating microRNAs as potential new biomarkers for prostate cancer. *Br J Cancer.* 2013; 108:1925–30. [PubMed: 23632485]
59. Mikeska T, Craig JM. DNA methylation biomarkers: cancer and beyond. *Genes.* 2014; 5:821–64. [PubMed: 25229548]
60. Nakamura J, Tanaka T, Kitajima Y, Noshiro H, Miyazaki K. Methylation-mediated gene silencing as biomarkers of gastric cancer: a review. *World J Gastroenterol.* 2014; 20:11991–2006. [PubMed: 25232236]
61. Wittenberger T, Sleight S, Reisel D, Zikan M, Wahl B, Alunni-Fabbroni M, et al. DNA methylation markers for early detection of women's cancer: promise and challenges. *Epigenomics.* 2014; 6:311–27. [PubMed: 25111485]
62. Allegra A, Alonci A, Campo S, Penna G, Petrungaro A, Gerace D, et al. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). *Int J Oncol.* 2012; 41:1897–912. [PubMed: 23026890]
63. Ward AF, Braun BS, Shannon KM. Targeting oncogenic Ras signaling in hematologic malignancies. *Blood.* 2012; 120:3397–406. [PubMed: 22898602]
64. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. *Lancet Oncol.* 2011; 12:175–80. [PubMed: 21277552]
65. Minuti G, D'Incecco A, Landi L, Cappuzzo F. Protein kinase inhibitors to treat non-small-cell lung cancer. *Expert Opin Pharmacother.* 2014; 15:1203–13. [PubMed: 24745764]
66. Zelinski DP, Zantek ND, Stewart JC, Irizarry AR, Kinch MS. EphA2 overexpression causes tumorigenesis of mammary epithelial cells. *Cancer Res.* 2001; 61:2301–6. [PubMed: 11280802]
67. Quintas-Cardama A, Cortes J. Review article Molecular biology of bcr-abl1 – positive chronic myeloid leukemia. *Blood.* 2009; 113:1619–31. [PubMed: 18827185]
68. Klezovitch O, Risk M, Coleman I, Lucas JM, Null M, True LD, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. *Proc Natl Acad Sci U S A.* 2008; 105:2105–10. [PubMed: 18245377]
69. Rivera MN, Haber DA. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. *Nat Rev Cancer.* 2005; 5:699–712. [PubMed: 16110318]
70. Minami A, Nakanishi A, Ogura Y, Kitagishi Y, Matsuda S. Connection between tumor suppressor BRCA1 and PTEN in damaged DNA repair. *Front Oncol.* 2014; 4:318. [PubMed: 25426449]
71. Liu Z, Li Q, Li K, Chen L, Li W, Hou M, et al. Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. *Oncogene.* 2013; 32:4203–13. [PubMed: 23045275]
72. Kim SA, Hong R. Significance of intracellular localization of survivin in cervical squamous cell lesions: Correlation with disease progression. *Oncol Lett.* 2014; 7:1589–93. [PubMed: 24765182]
73. Zhou Y, Bolton EC, Jones JO. Androgens and androgen receptor signaling in prostate tumorigenesis. *J Mol Endocrinol.* 2015; 54:R15–29. [PubMed: 25351819]
74. Xie S, Zhu M, Lv G, Geng Y, Chen G, Ma J, et al. Overexpression of Ras homologous C (RhoC) induces malignant transformation of hepatocytes in vitro and in nude mouse xenografts. *PLoS One.* 2013; 8:e54493. [PubMed: 23382905]
75. Small MB, Hay N, Schwab M, Bishop JM. Neoplastic transformation by the human gene N-myc. *Mol Cell Biol.* 1987; 7:1638–45. [PubMed: 3299052]

Figure 1.

Timeline of prophylactic vaccine administration within an early genetic and inflammatory model of cancer progression. This model of tumorigenesis highlights the early genetic and epigenetic changes that initiate the development of low-grade premalignant lesions. Within this early stage, oncogenic driver mutations along with epigenetic alterations cause neoplastic cells to secrete inflammatory cytokines to create an immunosuppressive TME characterized by an increasing desmoplastic response throughout cancer progression. Secreted inflammatory cytokines recruit immunosuppressive cell populations to the TME that reduce effector T-cell activation, increase immune tolerance, and drive immune evasion, all of which cumulatively serve to propagate carcinogenesis. The purple arrow indicates when infectious prophylactic vaccines are administered before exposure to virus, the causative agent. The red arrow indicates when cancer screening should be conducted to investigate the genetic and epigenetic signatures that may indicate presence of low-grade premalignant lesions, which if confirmed, could be the optimal time to initiate administration of non-infectious prophylactic vaccine regimen.

Table 1

Select driver antigens and their antigenic classifications. Driver antigens are expressed products of driver genes that have undergone early alterations or dysregulated-expression to initiate or facilitate tumorigenesis. Driver antigens are key to the neoplastic process and must support tumor growth. The classifications of driver antigens are determined by cell-type expression and subcellular localization. Tumor Specific Antigens (TSA) are exclusively expressed on tumor cells and not on any other cells. Tumor Associated Antigens (TAA) are endogenous antigens present on both tumor and normal cells. Candidate TAAs that are optimal targets for prophylactic vaccine development are overexpressed on tumor cells. Oncoantigens are specifically expressed extracellularly or on the cell surface. Select driver antigens that are discussed in this review along with other known driver antigens are used as examples for each class.

Driver Antigen	Oncogenic state	Cellular Location	Type of Antigen	Reference
Kras	Mutated	Plasma membrane	Oncoantigen	34,63
Nras	Mutated	Plasma membrane	Oncoantigen	63
HER-2/neu	Mutated, Overexpressed	Plasma membrane	Oncoantigen	26,64
EGFR	Mutated	Plasma membrane	Oncoantigen	65
MUC1	Overexpressed	Plasma membrane	Oncoantigen	3,17
EphA2	Overexpressed	Plasma membrane	Oncoantigen	17,66
ALK	Activated fusion protein	Plasma membrane	Oncoantigen	64,65
BRAF	Mutated	Cytoplasm	TSA	64
MEK1	Mutated	Cytoplasm	TSA	64
PI3K	Mutated	Cytoplasm	TSA	64
Akt	Mutated	Cytoplasm	TSA	64
bcr-abl	Activated fusion protein	Cytoplasm	TSA	17,67
ERG	Activated fusion protein	Nucleus	TSA	17,68
WT1	Mutated, Activated fusion protein	Nucleus	TSA	17,69
p53	Mutated	Nucleus	TSA	17
BRCA1	Mutated	Nucleus	TSA	70
PTEN	Mutated	Cytoplasm	TSA	70
hTERT	Overexpressed	Nucleus	TAA	17,71
Survivin	Overexpressed	Nucleus, Cytoplasm	TAA	17,72
Androgen Receptor	Overexpressed	Nucleus, Cytoplasm	TAA	17,73
RhoC	Overexpressed	Cytoplasm	TAA	17,74
MYCN	Overexpressed	Nucleus	TAA	17,75
Cyclin B1	Overexpressed	Nucleus, Cytoplasm	TAA	17